Ultrasound imaging technology developer Targeson has moved its research and manufacturing facilities to San Diego.
Targeson's commercial product line currently includes Targestar-P, a nontargeted ultrasound contrast agent designed to enhance contrast in the vasculature in preclinical applications. The agent can be used to image and quantify blood flow and vascular function.
Targestar SA is an ultrasound contrast agent coated with streptavidin to enable conjugation of targeting ligands for preclinical molecular imaging applications including tumor angiogenesis, myocardial infarction, atherosclerotic plaque, thrombosis, organ transplant rejection, and inflammatory bowel disease and other inflammatory disorders.
In addition, Targeson's Vivistar Integrin is a next-generation contrast agent for imaging angiogenesis.
Related Reading
Targeson launches US contrast agent, August 26, 2009
Targeson debuts US contrast agent, August 11, 2009
Copyright © 2009 AuntMinnie.com
